Apogenix to Present at Several Upcoming International Conferences
ACCESSWIRE
10 Oct 2019, 18:19 GMT+10
HEIDELBERG, GERMANY / ACCESSWIRE / October 10, 2019 / Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will attend several upcoming international conferences. In two presentations, Apogenix will give updates on TNF superfamily receptor agonists HERA-CD40L and HERA-GITRL. The company will further present a poster on the therapeutic benefit of orphan drugs in oncology.
Festival of Biologics (October 15-17, 2019)
Venue: Congress Center Basel, Basel, Switzerland
Attendees: Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering; Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization; Meinolf Thiemann, Ph.D., Director Protein Analytics
Presentation by Dr. Hill on October 16, 12:05 pm: 'HERA-CD40L: A Unique Hexavalent CD40 Agonist for Cancer Immunotherapy'
ISPOR Europe 2019 (November 2-6, 2019)
Venue: Bella Center Copenhagen, Copenhagen, Denmark
Attendee: Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment
Poster Presentation on November 4, 3:30 - 7:00 pm (Poster Author Discussion Hour: 6:00 - 7:00 pm): 'Therapeutic Benefit of Orphan Drugs in Oncology: Evidence at the Point of European Marketing Authorisation'
BIO-Europe 2019 (November 11-13, 2019)
Venue: Hamburg Messe, Hamburg, Germany
Attendees: Juergen Gamer, Ph.D., VP Business Development; Niclas Kneisel, Ph.D., Alliance Manager
11th Annual PEGS Europe (November 18-22, 2019)
Venue: Lisbon Congress Centre, Lisbon, Portugal
Attendees: Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering; Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization
Presentation by Dr. Hill on November 22, 2:35 pm: 'HERA-GITRL: A Unique Hexavalent GITR Agonist for Cancer Immunotherapy'
About Apogenix
Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of solid tumors and hematological malignancies. The company's pipeline of immuno-oncology drug candidates targets different tumor necrosis factor (TNF) superfamily-dependent signaling pathways, thereby restoring the immune response against tumors. Checkpoint inhibitor asunercept, the company's lead immuno-oncology candidate, is in late-stage clinical development with PRIME (PRIority MEdicines) designation by the European Medicines Agency for the treatment of glioblastoma. Based on its proprietary technology platform for the construction of novel TNF superfamily receptor agonists (HERA-ligands), Apogenix develops CD40, CD27, GITR, HVEM, and 4-1BB receptor agonists for cancer immunotherapy. The TRAIL receptor agonist program was outlicensed to AbbVie. AbbVie has initiated a phase I trial with TRAIL receptor agonist ABBV-621 in patients suffering from solid tumors, non-Hodgkins's lymphoma, or acute myeloid leukemia.
Contacts
Peter Willinger, CFO
Jennifer Mogk, PR Manager
Apogenix AG
Phone: +49 6221 58608-0
E-Mail: contact@apogenix.com
Web: www.apogenix.com
Media Contacts
Katja Arnold
Andreas Jungfer
MC Services AG
Phone: +49 89 210228-0
E-Mail: apogenix@mc-services.eu
SOURCE: Apogenix
View source version on accesswire.com:
https://www.accesswire.com/562687/Apogenix-to-Present-at-Several-Upcoming-International-Conferences
Subscribe and Follow
Get a daily dose of Hawaii Telegraph news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
News RELEASES
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Hawaii Telegraph.
More Information
21
℃
Russia suspected of blaming United States for coronavirus
U.S. government officials have suspected Russia of spreading fake news about the coronavirus, thus undermining international efforts to combat the ...
Racial minorities get behind Sanders in Nevada
TEHRAN (Tasnim) - Sen. Bernie Sanders (I-Vt.) posted a decisive victory in the Nevada caucuses Saturday, cementing his status as ...
Guterres criticizes war in Syria, demands political resolution
NEW YORK, New York - The head of the United Nations has issued a blunt message to warring parties in ...
Haitian leaders called on to reverse country's downfall
NEW YORK, New York - Leaders in Haiti must step up and end the political impasse between President Jovenel Mose ...
Delving in among the smoke and mirrors of the Pell case
Compound Probability and the CrownIn his appeal to the Intermediate Court, Bret Walker referred to 13 solid obstacles that pointed ...
Bayrob hackers infected 400,000 computers before being taken down
The hackers were like modern-day John Dillingers, brazenly committing their crimes and repeatedly escaping law enforcement's grasp.But like Dillinger and ...
Government instability in Malaysia rocks Asian markets
SYDNEY, Australia - Dramatic political events in Malaysia, and a widening of coronavirus cases and deaths beyond China put the ...
Multi-billion dollar settlement lets Wells Fargo off the hook
Wells Fargo Bank is to pay $3 billion, which includes $500 million to be distributed to investors, to settle potential ...
Human rights defender in Yemen whose son was shot to death is honored
TEHRAN (Tasnim) - A Yemeni lawyer won the prestigious Martin Ennals Award for 2020 in recognition of her efforts to ...
Wall Street and the dollar drop sharply, world markets follow
NEW YORK, New York - U.S. stocks fell sharply on Friday as profit-taking hit the U.S. dollar, finally puncturing what ...
Open-air markets in Central asia driving economic growth
Central Asia's lively, open-air markets are a dead giveaway to economists: signs of a large informal sector, or "shadow economy."These ...
Stock markets in Asia generally give up ground
SYDNEY, Australia - Stock markets were quiet on Friday, mostly trading in negative territory.In Japan the Nikkei 225 fell 92.41 ...
